GlaxoSmithKline Pharmaceuticals Limited (BOM:500660)
India · Delayed Price · Currency is INR | Market Cap | 430.26B -7.3% |
| Revenue (ttm) | 39.55B +5.8% |
| Net Income | 10.68B +12.4% |
| EPS | 63.05 +12.4% |
| Shares Out | 169.41M |
| PE Ratio | 40.20 |
| Forward PE | 35.51 |
| Dividend | 57.00 (2.24%) |
| Ex-Dividend Date | May 29, 2026 |
| Volume | 3,495 |
| Open | 2,510.25 |
| Previous Close | 2,534.65 |
| Day's Range | 2,489.00 - 2,563.90 |
| 52-Week Range | 2,088.00 - 3,121.10 |
| Beta | 0.08 |
| Analysts | Buy |
| Price Target | 3,097.25 (+21.95%) |
| Est. Earnings | Nov 4, 2026 |
About BOM:500660
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. ... [Read more]
Financial Performance
In fiscal year 2026, BOM:500660's revenue was 38.22 billion, an increase of 1.93% compared to the previous year's 37.49 billion. Earnings were 10.36 billion, an increase of 11.69%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for 500660 stock is "Buy." The 12-month stock price target is ₹3,097, which is an increase of 21.95% from the latest price.
News
GlaxoSmithKline Pharmaceuticals Transcript: Q1 26/27
Q1 FY 2027 saw 15% sales growth and 24% PAT growth, with innovation assets now 7% of revenue. Strong performance across General Medicines, Vaccines, and Specialty segments, with Shingrix and oncology assets driving momentum. EBITDA and PAT margins expanded, and new launches are expected to sustain double-digit growth.
GlaxoSmithKline Pharmaceuticals Slides: Q1 2027
GlaxoSmithKline Pharmaceuticals has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 3, 2026.
GlaxoSmithKline Pharmaceuticals Quarterly report: Q1 2027
GlaxoSmithKline Pharmaceuticals has published its Q1 2027 quarterly earnings report on August 3, 2026.
GlaxoSmithKline Pharmaceuticals Transcript: Q4 25/26
Revenue grew 2% for FY 2026, with double-digit EBITDA and PAT growth, driven by strong vaccines and specialty launches. Supply chain issues are resolved, and the innovative portfolio now contributes 6% of sales, with further growth expected from new launches.
GlaxoSmithKline Pharmaceuticals Quarterly report: Q4 2026
GlaxoSmithKline Pharmaceuticals has published its Q4 2026 quarterly earnings report on May 13, 2026.
GlaxoSmithKline Pharmaceuticals Slides: Q4 2026
GlaxoSmithKline Pharmaceuticals has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 13, 2026.
GlaxoSmithKline Pharmaceuticals Annual report: Q4 2026
GlaxoSmithKline Pharmaceuticals has published its Q4 2026 annual report on May 13, 2026.
GlaxoSmithKline Pharmaceuticals Transcript: Q3 25/26
Quarterly revenue surpassed INR 1,000 crores, with 8.1% standalone and nearly 10% consolidated growth, driven by recovery in general medicines, strong specialty and vaccine performance, and resolution of supply constraints. EBITDA margin improved to 35.9%, and new oncology launches are set to drive future growth.
GlaxoSmithKline Pharmaceuticals Quarterly report: Q3 2026
GlaxoSmithKline Pharmaceuticals has published its Q3 2026 quarterly earnings report on February 9, 2026.
GlaxoSmithKline Pharmaceuticals Slides: Q3 2026
GlaxoSmithKline Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 9, 2026.
GlaxoSmithKline Pharmaceuticals Transcript: Q2 25/26
Q2 sales declined 2.6% to INR 974 crore due to a CMO fire and market softness, but EBITDA margin improved to 34.4%. Vaccines and specialty segments grew strongly, and the oncology business launched in August is expected to drive future growth.
GlaxoSmithKline Pharmaceuticals Quarterly report: Q2 2026
GlaxoSmithKline Pharmaceuticals has published its Q2 2026 quarterly earnings report on November 5, 2025.
GlaxoSmithKline Pharmaceuticals Slides: Q2 2026
GlaxoSmithKline Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 5, 2025.
Pharma stocks rally: Glaxo surges 7%, Torrent gains after Q4; Gland steady post mixed results
Pharma stocks were trading firmly in the green on Tuesday morning, with GlaxoSmithKline Pharmaceuticals leading the charge—rising 7.4% to ₹2,992.80 as of 10:05 AM. The broader sector saw widespread bu...
GSK Pharma sets record date for Rs 12 special interim dividend on November 7, 2024
GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma) has announced the record date for its special interim dividend, set for November 7, 2024. This follows the company’s earlier declaration on October...